+Compare
TARA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
15.12M

TARA Protara Therapeutics Forecast, Technical & Fundamental Analysis

a clinical-stage company, which engages in developing treatments for rare and specialty diseases with significant unmet needs.

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for TARA with price predictions
07:00 PM EST Nov 27, 2023

TARA's RSI Oscillator ascending out of oversold territory

The RSI Indicator for TARA moved out of oversold territory on November 03, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on TARA as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TARA just turned positive on November 03, 2023. Looking at past instances where TARA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where TARA advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TARA broke above its upper Bollinger Band on November 27, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TARA entered a downward trend on November 27, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.166) is normal, around the industry mean (20.498). P/E Ratio (0.000) is within average values for comparable stocks, (137.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.811). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.636).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TARA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 33%, and the average quarterly price growth was 8%. AWKNF experienced the highest price growth at 165%, while AXLA experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -21% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

TARA is expected to report earnings to fall 8.91% to -79 cents per share on March 06

Protara Therapeutics TARA Stock Earnings Reports
Q4'23
Est.
$-0.79
Q3'23
Beat
by $0.11
Q2'23
Missed
by $0.12
Q1'23
Beat
by $0.08
Q4'22
Missed
by $2.71
The last earnings report on November 03 showed earnings per share of -87 cents, beating the estimate of -98 cents. With 21.94K shares outstanding, the current market capitalization sits at 15.12M.
A.I. Advisor
published General Information

General Information

a clinical-stage company, which engages in developing treatments for rare and specialty diseases with significant unmet needs.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
345 Park Avenue South
Phone
+1 646 844-0337
Employees
25
Web
http://www.protaratx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BNL15.84-0.03
-0.19%
Broadstone Net Lease
TS33.64-0.09
-0.27%
Tenaris S A
FMBH30.50-0.36
-1.17%
First Mid Bancshares
THRX3.72-0.08
-2.11%
Theseus Pharmaceuticals
VINC0.64-0.04
-5.41%
Vincerx Pharma

TARA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARA has been loosely correlated with ORMP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TARA jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARA
1D Price
Change %
TARA100%
+6.02%
ORMP - TARA
38%
Loosely correlated
-1.36%
BRNS - TARA
34%
Loosely correlated
+10.42%
MDGL - TARA
31%
Poorly correlated
-3.22%
SQZB - TARA
30%
Poorly correlated
-13.26%
CDTX - TARA
29%
Poorly correlated
-3.00%
More